News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


Genetic markers being used to target oral hepatitis C drug

Please note embargo:

Pharmac_P540c

Genetic markers being used to target new oral hepatitis C drug

A person’s genetic makeup will be used to target a new funded oral treatment for hepatitis C patients from 1 September.

PHARMAC will begin funding boceprevir (Victrelis) from 1 September 2013 for certain patients with the chronic liver infection. Boceprevir will be funded when used as a triple therapy in combination with pegylated interferon with ribavirin.

PHARMAC Medical Director Dr Peter Moodie says many hepatitis C patients do not respond well to current treatments, but that this could improve with the addition of boceprevir.

“Clinical evidence shows that, given the genetic characteristics of a patient, a simple genetic test can fairly accurately predict how they might respond to treatment,” says Dr Moodie.

“There is a group who we know respond poorly to current treatment. They are the ones we think will benefit most from the addition of this new treatment.”

About 25-35% of patients with certain genes showed a sustained response to the currently available treatment of pegylated interferon and ribavirin. By adding boceprevir to the treatment of these patients, the response rate increases to 70–75%.

As well as adding greater effectiveness to available treatments, Dr Moodie says boceprevir is the first funded oral treatment specifically for hepatitis C.

Patients will be genetically tested to determine whether they qualify for boceprevir (in combination with pegylated interferon and ribavirin) as a first-line treatment.

Boceprevir will also be funded for people who have tried but not responded completely to a course of pegylated interferon and ribavirin.

Dr Moodie says though many people live with hepatitis C without ever knowing it, the infection can cause significant health issues including hepatocellular carcinoma, liver failure, which may require a liver transplant.

Pharmacological treatment aims to reduce the likelihood of these transplants being required. In total, PHARMAC expects around 300 patients to start triple therapy in the next year.

In addition to funding boceprevir, PHARMAC has negotiated a price reduction for the Pegasys brand of pegylated interferon with ribavirin. Together, the funding of these hepatitis C treatments will cost $17.8 million over five years, with some of this cost being refunded through confidential rebates negotiated with both suppliers.

ENDS


© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Scoop Review Of Books: From Here And There

Being Chinese: A New Zealander’s Story
by Helene Wong.
This is the fascinating story of Helene Wong, born in 1949 in Taihape to Chinese parents: her mother, born soon after her parents migrated here, and her father, born in China but sent to relatives in Taihape at seven to get an education in English. More>>

Chiku: Hamilton Zoo's Baby Chimpanzee Named

Hamilton Zoo has named its three-month-old baby chimpanzee after a month-long public naming competition through the popular zoo’s website. The name chosen is Chiku, a Swahili name for girls meaning "talker" or "one who chatters". More>>

Game Over: Trans-Tasman Netball League To Discontinue

Netball Australia and Netball New Zealand have confirmed that the existing ANZ Championship format will discontinue after the current 2016 season, with both organisations to form national netball leagues in their respective countries. More>>

NZSO Review: Stephen Hough Is Perfection-Plus

He took risks, and leant into the music when required. But you also felt that every moment of his playing made sense in the wider picture of the piece. Playing alongside him, the NZSO were wonderful as ever, and their guest conductor, Gustavo Gimeno, coaxed from them a slightly darker, edgier sound than I’m used to hearing. More>>

ALSO:

Howard Davis Review: King Lear At Circa

In order to celebrate it's 40th birthday, it is perhaps fitting that Circa Theatre should pick a production of 'King Lear,' since it's also somewhat fortuitously Shakespeare's 400th anniversary. If some of the more cerebral poetry is lost in Michael Hurst's streamlined, full throttle production, it's more than made up for by plenty of lascivious violence designed to entertain the groundlings. More>>

Scoop Review Of Books: Tauranga Books Festival

Escape to Tauranga for Queen’s Birthday weekend and an ideas and books-focused festival that includes performance, discussion, story-telling, workshops and an Italian-theme morning tea. More>>

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news